Is Trident Texofab overvalued or undervalued?

As of 29 August 2025, the valuation grade for Trident Texofab has moved from very expensive to expensive. The company is currently considered overvalued based on its high valuation ratios. Notable ratios include a PE ratio of 133.86, an EV to EBITDA of 76.80, and a PEG ratio of 6.36, all of which indicate a premium valuation compared to typical industry standards. In comparison to peers, Trident Texofab's PE ratio significantly exceeds that of PTC India, which is very attractive at 8.35, and Lloyds Enterprises, which is very expensive at 38.87. This stark contrast highlights the overvaluation of Trident Texofab. Additionally, the company's recent stock performance has been impressive, with a 1-year return of 456.44%, far outpacing the Sensex's decline of 2.83%, although this does not mitigate the concerns regarding its current valuation.